EGFR and pulmonary fibrosis: Several studies have demonstrated that EGFR is highly expressed and that EGFR signaling activity contributes to lung fibrosis in COVID-19 patients, leading to the identification of EGFR as a potential therapeutic target for treating severe COVID-19 (33, 35, 36).